Improving recombinant protein production in CHO cells using the CRISPR-Cas system

Area of Science:

• Biotechnology and Genetic Engineering
• Mammalian Cell Line Development
• Biopharmaceutical Production

Background:

• Chinese hamster ovary (CHO) cells are critical for biopharmaceutical manufacturing.
• Genetic engineering, particularly CRISPR-Cas systems, offers powerful tools for CHO cell line improvement.
• Optimizing recombinant protein (r-protein) production is essential for cost-effective biopharmaceutical development.

Purpose of the Study:

• To review recent advancements in CRISPR-Cas systems for enhancing r-protein production in CHO cells.
• To analyze the advantages, limitations, and bottlenecks of various CRISPR-Cas strategies.
• To discuss the impact of CRISPR-mediated gene editing on glycan composition and r-protein properties.

Main Methods:

• Review of key studies utilizing CRISPR-Cas9, CRISPR-Cas13, and dCas9-effector systems.
• Analysis of CRISPR applications across different stages of r-protein production.
• Focus on gene disruption and regulation related to glycan modification in CHO cells.

Main Results:

• CRISPR-Cas technology provides flexible and efficient genetic manipulation for CHO cells.
• Engineered CHO cells show improved r-protein production yields.
• CRISPR can modulate glycan profiles, impacting r-protein function and activity.

Conclusions:

• CRISPR-Cas systems are mature strategies for improving CHO cell productivity in biopharmaceutical manufacturing.
• Further research is needed to fully realize the potential of emerging CRISPR techniques in CHO cells.
• CRISPR technology contributes to more cost-efficient biopharmaceutical production through enhanced CHO cell lines.